Insider Trading Alert - AVNR, ALK, BIIB, VRX And RAI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 5, 2013, 166 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $50.32 to $1,887,935,195.16.

Highlighted Stocks Traded by Insiders:

AVANIR Pharmaceuticals (AVNR) - FREE Research Report

Katkin Keith who is President and CEO at AVANIR Pharmaceuticals sold 4,385 shares at $4.14 on Nov. 5, 2013. Following this transaction, the President and CEO owned 475,222 shares meaning that the stake was reduced by 0.91% with the 4,385 share transaction.

Palekar Rohan who is SVP & Chief Commercial Officer at AVANIR Pharmaceuticals bought 10,000 shares at $4.19 on Nov. 5, 2013. Following this transaction, the SVP & Chief Commercial Officer owned 133,000 shares meaning that the stake was reduced by 8.13% with the 10,000 share transaction.

The shares most recently traded at $4.23, up $0.04, or 0.96% since the insider transaction. Historical insider transactions for AVANIR Pharmaceuticals go as follows:

  • 24-Week # shares sold: 15,500

The average volume for AVANIR Pharmaceuticals has been 3.2 million shares per day over the past 30 days. AVANIR Pharmaceuticals has a market cap of $613.2 million and is part of the health care sector and drugs industry. Shares are up 61.09% year to date as of the close of trading on Tuesday.

Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. Currently there are 3 analysts that rate AVANIR Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AVNR - FREE

TheStreet Quant Ratings rates AVANIR Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally high debt management risk. Get the full AVANIR Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Alaska Air Group (ALK) - FREE Research Report

Harrison Andrew R who is Vp/Plng & Rev Mgmt at Alaska Air Group sold 500 shares at $73.02 on Nov. 5, 2013. Following this transaction, the Vp/Plng & Rev Mgmt owned 3,482 shares meaning that the stake was reduced by 12.56% with the 500 share transaction.

The shares most recently traded at $72.03, down $0.99, or 1.37% since the insider transaction. Historical insider transactions for Alaska Air Group go as follows:

  • 4-Week # shares sold: 2,054
  • 12-Week # shares sold: 3,754
  • 24-Week # shares sold: 9,830

The average volume for Alaska Air Group has been 671,600 shares per day over the past 30 days. Shares are up 68.9% year to date as of the close of trading on Tuesday.

Alaska Air Group, Inc., through its subsidiaries, provides scheduled air transportation for passengers and cargo. The stock currently has a dividend yield of 1.1%. The company has a P/E ratio of 10.9. Currently there are 4 analysts that rate Alaska Air Group a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALK - FREE

TheStreet Quant Ratings rates Alaska Air Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Alaska Air Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Biogen Idec (BIIB) - FREE Research Report

Scangos George A who is Chief Executive Officer at Biogen Idec sold 2,239 shares at $245.57 on Nov. 5, 2013. Following this transaction, the Chief Executive Officer owned 39,044 shares meaning that the stake was reduced by 5.42% with the 2,239 share transaction.

Schenk Lynn who is Director at Biogen Idec sold 1,000 shares at $245.00 on Nov. 5, 2013. Following this transaction, the Director owned 5,100 shares meaning that the stake was reduced by 16.39% with the 1,000 share transaction.

The shares most recently traded at $242.00, down $3.00, or 1.24% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 12-Week # shares sold: 14,687
  • 24-Week # shares sold: 32,993

The average volume for Biogen Idec has been 1.1 million shares per day over the past 30 days. Biogen Idec has a market cap of $56.7 billion and is part of the health care sector and drugs industry. Shares are up 64.02% year to date as of the close of trading on Tuesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 33.7. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Provencio Norma Ann who is Director at Valeant Pharmaceuticals International sold 5,000 shares at $106.70 on Nov. 5, 2013. Following this transaction, the Director owned 158,647 shares meaning that the stake was reduced by 3.06% with the 5,000 share transaction.

The shares most recently traded at $108.48, up $1.78, or 1.64% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 12-Week # shares bought: 59,532
  • 12-Week # shares sold: 9,000
  • 24-Week # shares bought: 70,472
  • 24-Week # shares sold: 15,000

The average volume for Valeant Pharmaceuticals International has been 1.2 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $36.8 billion and is part of the health care sector and drugs industry. Shares are up 83.12% year to date as of the close of trading on Tuesday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. The stock currently has a dividend yield of 0.95%. Currently there are 10 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Reynolds American (RAI) - FREE Research Report

Brown & Williamson Holdings, Inc. who is 10% Owner at Reynolds American sold 122,491 shares at $51.47 on Nov. 5, 2013. Following this transaction, the 10% Owner owned 226.8 million shares meaning that the stake was reduced by 0.05% with the 122,491 share transaction.

The shares most recently traded at $51.72, up $0.25, or 0.48% since the insider transaction. Historical insider transactions for Reynolds American go as follows:

  • 4-Week # shares sold: 376,540
  • 12-Week # shares sold: 1.2 million
  • 24-Week # shares sold: 2.8 million

The average volume for Reynolds American has been 1.5 million shares per day over the past 30 days. Shares are up 24.06% year to date as of the close of trading on Tuesday.

Reynolds American Inc., through its subsidiaries, manufactures and sells cigarette and other tobacco products in the United States. The company operates through RJR Tobacco, American Snuff, and Santa Fe segments. The stock currently has a dividend yield of 4.94%. The company has a P/E ratio of 17.8. Currently there are 2 analysts that rate Reynolds American a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RAI - FREE

TheStreet Quant Ratings rates Reynolds American as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Reynolds American Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers